AZ Bets Big On ADCs As It Inks Second, $6bn Deal With Daiichi
$1bn Upfront To Secure New Asset
Following their original March 2019 tie-up for an oncology antibody-drug conjugate, Daiichi Sankyo and AstraZeneca have entered into a new global deal worth up to $6bn for a second novel asset from the Japanese firm, with potential in breast, lung and other cancers.
You may also be interested in...
Also, Osmotica licenses rights to ophthalmic drug in Japan, China and the EMEA nations to Santen; Lilly and Chi-Med revise their partnership around colorectal cancer drug Elunate.
Trodelvy was granted an accelerated approval by the US FDA based on a Phase II study. It is the first commercial product for Immunomedics.
In a further positive step for its oncology ambitions, Japanese company files first submission for promising lead antibody-drug conjugate, partnered globally with AstraZeneca, while other pipeline ADCs mark development progress.